Yoji Morisaki

Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52‐week, open‐label, phase 3 study (<scp>UNCOVER</scp>‐J)

Hidehisa Saeki, Hidemi Nakagawa, Ko Nakajo et al. · The Journal of Dermatology · 2016 · 193 citations · Full text

Medicine, Dermatology, Pharmacotherapy +15

Efficacy and safety of open‐label ixekizumab treatment in Japanese patients with moderate‐to‐severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis

Hidehisa Saeki, Hidemi Nakagawa, Taeko Ishii et al. · Journal of the European Academy of Dermatology and Venereology · 2014 · 132 citations

Medicine, Dermatology, Pharmacology +12

Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A randomized placebo‐ and tamsulosin‐controlled 12‐week study in <scp>A</scp>sian men

Osamu Yokoyama, Masaki Yoshida, Sae Chul Kim et al. · International Journal of Urology · 2012 · 84 citations

Medicine, Pharmacology, Pharmacotherapy +12

Long‐term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open‐label, phase 3 study (<scp>UNCOVER</scp>‐J)

Yukari Okubo, Tomotaka Mabuchi, Keiji Iwatsuki et al. · Journal of the European Academy of Dermatology and Venereology · 2018 · 62 citations · Full text

Medicine, Dermatology, Pharmacotherapy +8

Tadalafil 5 mg once‐daily therapy for men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: Results from a randomized, double‐blind, placebo‐controlled trial carried out in <scp>J</scp>apan and <scp>K</scp>orea

Masayuki Takeda, Osamu Yokoyama, Sung Won Lee et al. · International Journal of Urology · 2014 · 44 citations · Full text

Medicine, Pharmacotherapy, Urology +11